UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): January 12, 2015
CardioGenics
Holdings Inc.
(Exact
Name of Registrant as Specified in its Charter)
Nevada |
|
000-28761 |
|
88-0380546 |
(State or other
jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification) |
6295
Northam Drive, Unit 8, Mississauga, Ontario, L4V 1W8
(Address
of Principal Executive Offices)(Zip Code)
Registrant’s
telephone number, including area code: 905.673.8501
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE
OF CONTENTS
Item
5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
On
January 12, 2015 the board of directors (the “Board”) of CardioGenics Holdings Inc. (the “Company”) appointed
Karim Murabet as a director of the Company. Mr. Murabet will serve as an independent director of the Company.
Mr.
Murabet has extensive business experience in diverse fields. He began his career as a professional soccer player around the world
and went on to work in the sporting goods industry as the owner of Lanzera Italia. He also served as a football manager in various
countries. As an investor, he is currently co-owner of Libyan Italian Real Estate Investment Co. and a consultant and advisor to
Gruppo Bonifaci, one of Italy’s largest real estate developers based in Rome.
Mr.
Murabet currently resides in the United Arab Emirates and is a Partner and Director responsible for business development and
public relations in ICap Group FZC, a property development, architecture, hotel management and investment company registered
in the United Arab Emirates.
Mr.
Murabet is a graduate of College du leman in Versoix, Switzerland and received a BA in human behavior and later an MBA in business
from U.S. International University-San Diego.
Item
7.01 – Regulation FD Disclosure
On
January 12, 2015, the Company issued a press release reporting the appointment of Karim Murabet as a director of the Company.
A copy of the press release is attached hereto as Exhibit 99.1.
The
information in Exhibit 99.1 shall not be deemed as “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934 (the “Exchange Act”), or otherwise subject to the liability of such Section, nor shall it be deemed
incorporated by reference in any filing by us under the Securities Act, as amended, or the Exchange Act, regardless of any general
incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
Item
9.01 Exhibits.
(d) Exhibits
99.1 | Press
Release dated January 12, 2015. |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CARDIOGENICS
HOLDINGS INC. |
|
|
|
|
By: |
/s/
Yahia Gawad |
|
Name: |
Yahia Gawad |
|
Title: |
Chief Executive
Officer |
Dated: January
12, 2015
EXHIBIT
99.1
CardioGenics
Announces Appointment of New Director
MISSISSAUGA,
Ontario – January 12, 2015 – CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care™
analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced
today that Karim Murabet has been appointed as a director of the Company, effective January 12, 2015. Mr. Murabet will serve as
an independent director.
Dr.
Yahia Gawad, Chief Executive Officer of CardioGenics, commented, “We are extremely pleased to have an individual of Karim’s
reputation and experience joining CardioGenics. Karim brings a strong background in international business that will enhance the
expertise, knowledge and skills of our board. We look forward to working with Karim as we move forward with the commercialization
of our products and our growth strategy.”
Mr.
Murabet has extensive business experience in diverse fields. He began his career as a professional soccer player around the world
and went on to work in the sporting goods industry as the owner of Lanzera Italia. His passion for sports also led him to be a
football manager in various countries. As an investor, he is currently co-owner of Libyan Italian Real Estate Investment Co. and
a consultant and advisor to Gruppo Bonifaci, one of Italy’s largest real estate developers, based in Rome.
Mr.
Murabet currently resides in the United Arab Emirates and is a Partner and Director responsible for business development and public
relations in ICap Group FZC, a property development, architecture, hotel management and investment company registered in the United
Arab Emirates.
Mr.
Murabet is a graduate of College du leman in Versoix, Switzerland and received a BA in human behavior and later an MBA in business
from U.S. International University-San Diego.
ABOUT
CARDIOGENICS HOLDINGS INC.
Through
its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment
of the IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer,
which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic
tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic
microspheres (a fundamental component of immunoassay equipment), which improve instrument sensitivity to light. The Company’s
proprietary microspheres technology and SAVAsphere™ magnetic beads are developed and marketed through the Company’s
Luxspheres subsidiary. The Company’s principal offices are located in Mississauga, Ontario, Canada. For more information
please visit www.cardiogenics.com and www.luxspheres.com.
Safe
Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private
Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as “anticipate, “believe,”
“expect,” “future,” “may,” “will,” “should,” “plan,” “projected,”
“intend,” and similar expressions to identify forward-looking statements. These statements are based on the Company’s
beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company’s
current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could
differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed
on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made
to the Company’s periodic filings with the Securities and Exchange Commission.
For
more information about CardioGenics:
CardioGenics
Holdings Inc.
Joseph
J. Nese
Tel:
1.516.428.4200
CardioGenics (CE) (USOTC:CGNH)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
CardioGenics (CE) (USOTC:CGNH)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025